Renalytix AI PLC (RNLX)
|Net Income (ttm)||-8.19M|
|Day's Range||25.04 - 27.83|
|52-Week Range||10.31 - 35.71|
|Price Target||38.00 (+38.7%)|
|Est. Earnings Date||n/a|
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products ... [Read more...]
Financial PerformanceFinancial Statements
According to 3 analysts, the average rating for Renalytix AI stock is "Buy." The 12-month stock price forecast is 38.00, which is an increase of 38.69% from the latest price.
LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical man...
LONDON and SALT LAKE CITY, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release fourth quarter and full year fiscal 2021 financial results ...
Jed Fulk Appointed Vice President Sales, Government Accounts Jed Fulk Appointed Vice President Sales, Government Accounts
Analyst estimates suggest these stocks can deliver eye-popping gains once the rest of the stock market views them in the same light.
Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021 Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021
All three are rapidly expanding into their own corners of America's $4 trillion per year healthcare sector.
NEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 202...
Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic Levangie brings extensive commercial operating experience to R...
There's a stock on this list analysts think can climb by around 47%, as soon as more investors come around to their way of seeing things.
Payer Budget Impact Analysis Projects Significant Savings from KidneyIntelX™ Testing at Primary Care Level
Peer reviewed publication in Journal of Medical Economics supports payer coverage for early-stage risk assessment and care management in the primary care office Peer reviewed publication in Journal of M...
NEW YORK, July 26, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 41st Annual Canaccord G...
Shares of these overlooked gems could make investors very rich once the rest of the market notices their value.
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021.
Announces Change of Auditor to Ernst & Young LLP Announces Change of Auditor to Ernst & Young LLP
Leadership Additions Announced to Support Expanding US Government and Healthcare Provider KidneyIntelX Deployment
Enabling expertise in sales, population health and value-driven care models Enabling expertise in sales, population health and value-driven care models
Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care
Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment to improve patient outcomes and reduce healthcare costs Clinicians affirm need for accurate early-stage diabetic k...
Atrium Health, Wake Forest Baptist Health, Wake Forest School of Medicine and Renalytix Partner to Advance Kidney Health
Partnership marks a long-term commitment to reducing impact of kidney disease in large populations via integration of earlier risk assessment paired with comprehensive disease management Partnership mar...
Kantaro's COVID-SeroKlir Antibody Test Named As A Finalist For Fast Company's 2021 World Changing Ideas Awards
NEW YORK, May 4, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX) (NASDAQ: RNLX), announced today that COVID-SeroKlir, its...
Renalytix AI plc (NASDAQ: RNLX) stock is rising on the heels of a 10-year contract from the United States Government to provide KidneyIntelX early-stage kidney disease bioprognostic testing services. Th...
KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular A...
Data from 1,325 CANVAS Participants with Baseline DKD Scored with KidneyIntelX Presented at International Society of Nephrology World Congress of Nephrology 2021 Data from 1,325 CANVAS Participants with...
RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio for KidneyIntelX Platform
Agreement provides RenalytixAI with exclusive option to access intellectual property surrounding a comprehensive panel of novel biomarkers in kidney disease Agreement provides RenalytixAI with exclusive...
Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions
Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings Value of KidneyIntelX Testing Demonstrated by Data from ...